Dec. 22 at 6:25 PM
$LUNG Some decent news came out today..
1. The FDA & PROLIFIC News (Released Today, Dec 22)
The Prognostic Lung Fibrosis Consortium (PROLIFIC) announced today that the FDA has accepted their Letter of Intent to qualify the "PROLIFIC Risk Score" as a formal drug development tool.
What it is: This is a blood-based "score" that predicts how fast a patient’s lung disease (specifically Idiopathic Pulmonary Fibrosis or IPF) will progress.
Why it matters for
$LUNG: Pulmonx’s primary business is the Zephyr Valve, which treats emphysema (a form of COPD). However, the company is moving toward being a "total lung health" company.